Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease (original) (raw)

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109.
  Article PubMed Google Scholar
• Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491–7. https://doi.org/10.1001/jama.2012.39.
  Article PubMed Google Scholar
• Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. Diabetes Obes Metab n/a(n/a). https://doi.org/10.1111/dom.14521
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367.
  Article PubMed Google Scholar
• Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9. https://doi.org/10.1002/hep.1840220616.
  Article CAS PubMed Google Scholar
• Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017–23. https://doi.org/10.1007/s10620-013-2743-5.
  Article CAS PubMed Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, AJ MC. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9. https://doi.org/10.1016/S0016-5085(99)70506-8.
  Article CAS PubMed Google Scholar
• Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3(4):e00105. https://doi.org/10.1002/edm2.105.
  Article PubMed Google Scholar
• Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin N Am. 2020;49(1):1–23. https://doi.org/10.1016/j.gtc.2019.09.007.
  Article Google Scholar
• Rinella ME, Lominadze Z, Loomba R, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Ther Adv Gastroenterol. 2016;9(1):4–12. https://doi.org/10.1177/1756283x15611581.
  Article CAS Google Scholar
• • Kai Toh JZ, Pan XH, Lin Tay PW, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.09.021. Findings from this study suggests that moderate to severe steatosis is related to clinical coronary artery disease which prompts for timely screening and intervention.
• Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know. Diabetes Obes Metab. 2022;24 Suppl 2:3–14. https://doi.org/10.1111/dom.14521.
• CD B, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-S64.
• Petta S, Valenti L, Bugianesi E, et al. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis. 2016;48(3):333–42.
  Article PubMed Google Scholar
• Mikolasevic I, Milic S, Wensveen TT, et al. Nonalcoholic fatty liver disease-a multisystem disease? World J Gastroenterol. 2016;22(43):9488.
  Article CAS PubMed PubMed Central Google Scholar
• Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174–97.
  Article CAS PubMed Google Scholar
• Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.
  Article PubMed Google Scholar
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004
• Lonardo A, Nascimbeni F, Targher G, et al. AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017;49(5):471–83.
  Article Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.
  Article CAS PubMed Google Scholar
• Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol. 2017;6(2):62.
  Article PubMed PubMed Central Google Scholar
• Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258–67.
  Article CAS PubMed Google Scholar
• Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin. 2020;49(1):1–23.
  Article Google Scholar
• Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56(1):234–40.
  Article PubMed Google Scholar
• Muthiah MD, Sanyal AJ. Current management of non-alcoholic steatohepatitis. Liver Int. 2020;40:89–95.
  Article PubMed PubMed Central Google Scholar
• Siddiqui MS, Harrison SA, Abdelmalek MF, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001–12.
  Article PubMed Google Scholar
• Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021;18(6):373–92.
  Article PubMed Google Scholar
• Most J, Gilmore LA, Smith SR, Han H, Ravussin E, Redman LM. Significant improvement in cardiometabolic health in healthy nonobese individuals during caloric restriction-induced weight loss and weight loss maintenance. Am J Physiol-Endocrinol Metab. 2018;314(4):E396–405. https://doi.org/10.1152/ajpendo.00261.2017.
  Article CAS PubMed Google Scholar
• Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904. https://doi.org/10.1007/s00125-011-2446-4.
  Article CAS PubMed Google Scholar
• Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(4):1024–30. https://doi.org/10.1007/s10620-014-3380-3.
  Article CAS PubMed Google Scholar
• Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011;108(10):1499–507. https://doi.org/10.1016/j.amjcard.2011.06.076.
  Article PubMed Google Scholar
• Mahajan R, Lau DH, Sanders P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc Med. 2015;25(2):119–26. https://doi.org/10.1016/j.tcm.2014.09.005.
  Article CAS PubMed Google Scholar
• Karimian S, Stein J, Bauer B, Teupe C. Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes Metab Syndr Obes. 2017;10:19–25. https://doi.org/10.2147/dmso.S124541.
  Article PubMed PubMed Central Google Scholar
• Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387(10031):1947–56. https://doi.org/10.1016/S0140-6736(16)00271-3.
  Article PubMed Google Scholar
• Bleich SN, Bandara S, Bennett W, Cooper LA, Gudzune KA. Enhancing the role of nutrition professionals in weight management: A cross-sectional survey. Obesity. 2015;23(2):454–60. https://doi.org/10.1002/oby.20945.
  Article PubMed Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5. https://doi.org/10.1053/j.gastro.2015.04.005.
  Article PubMed Google Scholar
• Keating SE, Hackett DA, Parker HM, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63(1):174–82. https://doi.org/10.1016/j.jhep.2015.02.022.
  Article PubMed Google Scholar
• Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66(1):142–52. https://doi.org/10.1016/j.jhep.2016.08.023.
  Article PubMed Google Scholar
• Weiss EC, Galuska DA, Kettel Khan L, Gillespie C, Serdula MK. Weight regain in U.S. Adults Who Experienced Substantial Weight Loss, 1999–2002. Am J Prev Med. 2007;33(1):34–40. https://doi.org/10.1016/j.amepre.2007.02.040.
  Article PubMed Google Scholar
• Xiao J, Lim LKE, Ng CH, et al. Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease. Systematic Review. Front Med. 2021;8(912). https://doi.org/10.3389/fmed.2021.691696.
• Foster-Schubert KE, Alfano CM, Duggan CR, et al. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity. 2012;20(8):1628–38. https://doi.org/10.1038/oby.2011.76.
  Article CAS PubMed Google Scholar
• Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58(9):1281–8. https://doi.org/10.1136/gut.2008.151977.
  Article CAS PubMed Google Scholar
• Rosenzweig JL, Ferrannini E, Grundy SM, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(10):3671–89. https://doi.org/10.1210/jc.2008-0222.
  Article CAS PubMed Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25_suppl_2):S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.
  Article PubMed Google Scholar
• de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp. 2010;25(5):730–5.
  PubMed Google Scholar
• Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. https://doi.org/10.1056/NEJMoa1800389.
  Article CAS PubMed Google Scholar
• Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):194–9. https://doi.org/10.1016/j.dld.2007.10.003.
  Article CAS PubMed Google Scholar
• Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015;62(1):190–7. https://doi.org/10.1016/j.jhep.2014.08.036.
  Article CAS PubMed Google Scholar
• Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Treatment of dyslipidemia in common liver diseases. Clin Gastroenterol Hepatol. 2018;16(8):1189–96. https://doi.org/10.1016/j.cgh.2018.04.023.
  Article PubMed PubMed Central Google Scholar
• Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46. https://doi.org/10.1016/j.jhep.2017.05.016.
  Article PubMed Google Scholar
• O'Keefe JH, Bhatti SK, Patil HR, DiNicolantonio JJ, Lucan SC, Lavie CJ. Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J Am Coll Cardiol. 2013;62(12):1043–51. https://doi.org/10.1016/j.jacc.2013.06.035.
  Article PubMed Google Scholar
• Siddiqui MS, Carbone S, Vincent R, et al. Prevalence and severity of nonalcoholic fatty liver disease among caregivers of patients with nonalcoholic fatty liver disease cirrhosis. Clin Gastroenterol Hepatol. 2019;17(10):2132–3. https://doi.org/10.1016/j.cgh.2018.11.008.
  Article PubMed Google Scholar
• Cusi K. Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes. Wiley Online. Library. 2019:2318–22.
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90.
  Article CAS PubMed Google Scholar
• Capehorn M, Catarig A-M, Furberg J, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.
  Article CAS PubMed Google Scholar
• O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–49.
  Article CAS PubMed Google Scholar
• Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211–34.
  Article CAS PubMed Google Scholar
• Newsome P, Francque S, Harrison S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019;50(2):193–203.
  Article CAS PubMed PubMed Central Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24.
  Article CAS PubMed Google Scholar
• Nisoli E, Carruba M. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000;1(2):127–39.
  Article CAS PubMed Google Scholar
• Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A Double-Blind Randomized Placebo-Controlled Trial of Sibutramine. Obes Res. 1996;4(3):263–70. https://doi.org/10.1002/j.1550-8528.1996.tb00544.x.
  Article CAS PubMed Google Scholar
• James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–17.
  Article CAS PubMed Google Scholar
• Bajracharya O, Shankar PR, Jha N. Cardiovascular toxicity of noncardiovascular drugs. Heart Toxins Elsevier. 2015:305–39.
• Harp JB. Orlistat for the long-term treatment of obesity. Drugs Today (Barc). 1999;35(2):139–45.
  Article CAS Google Scholar
• Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management. Accessed 6 January 2021, https://www.gelesis.com/2019/04/14/gelesis-granted-fda-clearance-to-market-plenitytm-a-new-prescription-aid-to-weight-management/
• Greenway FL, Aronne LJ, Raben A, et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity. 2019;27(2):205–16.
  Article CAS PubMed Google Scholar
• Wong C, Yaow CYL, Ng CH, et al. Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis. Systematic Review. Front Endocrinol. 2021;11(1098). https://doi.org/10.3389/fendo.2020.609135.
• • Ng CH, Lin SY, Chin YH, et al. Antidiabetic medications for type 2 diabetics with nonalcoholic fatty liver disease: evidence from a network meta-analysis of randomized controlled trials. Endocr Pract. https://doi.org/10.1016/j.eprac.2021.09.013. This study demonstrated that glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors had benefit in improvement in steatosis and lipid modulation in NAFLD patients.
• Ng CH, Lin SY, Chin YH, et al. Antidiabetic medications for type 2 diabetics with nonalcoholic fatty liver disease: evidence from a network meta-analysis of randomized controlled trials. Endocr Pract. 2021. https://doi.org/10.1016/j.eprac.2021.09.013.
• Basu D, Huggins L-A, Scerbo D, et al. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207–16.
  Article CAS PubMed PubMed Central Google Scholar
• Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098–107.
  Article CAS PubMed Google Scholar
• Matsuzaka T, Shimano H. Molecular mechanisms involved in hepatic steatosis and insulin resistance. J Diabetes Investig. 2011;2(3):170–5.
  Article CAS PubMed PubMed Central Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–30.
  Article CAS PubMed PubMed Central Google Scholar
• Koutoukidis DA, Astbury NM, Tudor KE, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(9):1262–71.
  Article PubMed PubMed Central Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78 e5.
  Article PubMed Google Scholar
• Kelly KR, Navaneethan SD, Solomon TP, et al. Lifestyle-induced decrease in fat mass improves adiponectin secretion in obese adults. Med Sci Sports Exerc. 2014;46(5):920.
  Article CAS PubMed PubMed Central Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.
  Article CAS PubMed Google Scholar
• Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93. https://doi.org/10.1056/NEJMoa035622.
  Article PubMed Google Scholar
• Adams TD, Pendleton RC, Strong MB, et al. Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese. Obesity. 2010;18(1):121–30. https://doi.org/10.1038/oby.2009.178.
  Article PubMed Google Scholar
• Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of weight loss on predicted cardiovascular risk: change in cardiac risk after bariatric surgery. Obesity. 2007;15(3):772–84. https://doi.org/10.1038/oby.2007.589.
  Article PubMed Google Scholar
• Busetto L, Sergi G, Enzi G, et al. Short-term effects of weight loss on the cardiovascular risk factors in morbidly obese patients. Obes Res. 2004;12(8):1256–63. https://doi.org/10.1038/oby.2004.159.
  Article PubMed Google Scholar
• Torquati A, Wright K, Melvin W, Richards W. Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II to III obesity. J Am Coll Surg. 2007;204(5):776–82. https://doi.org/10.1016/j.jamcollsurg.2006.12.038.
  Article PubMed Google Scholar
• Kaier TE, Morgan D, Grapsa J, et al. Ventricular remodelling post-bariatric surgery: is the type of surgery relevant? A prospective study with 3D speckle tracking. Eur Heart J Cardiovasc Imaging. 2014;15(11):1256–62.
  Article PubMed Google Scholar
• Owan T, Avelar E, Morley K, et al. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. J Am Coll Cardiol. 2011;57(6):732–9.
  Article PubMed PubMed Central Google Scholar
• Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–1060.e11. https://doi.org/10.1016/j.cgh.2018.10.017.
  Article PubMed Google Scholar
• Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031–42. https://doi.org/10.1001/jama.2021.19569.
  Article PubMed PubMed Central Google Scholar
• O’Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3–14.
  Article PubMed Google Scholar
• Surgery B. Risks and rewards Pories Walter J. J Clin Endocrinol Metab. 2008;93(11_supplement_1):s89–96.
  Google Scholar
• Kabir A, Mousavi S, Pazouki A. The complications of bariatric surgery patients with type 2 diabetes in the world: a systematic review and meta-analysis. Curr Diabetes Rev. 2019;15(1):49–61.
  Article PubMed Google Scholar
• Castaneda D, Popov VB, Wander P, Thompson CC. Risk of suicide and self-harm is increased after bariatric surgery-a systematic review and meta-analysis. Obes Surg Jan 2019;29(1):322-333. doi:https://doi.org/10.1007/s11695-018-3493-4
• Lee Y-M, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76(4):756–60. https://doi.org/10.1016/j.gie.2012.05.023.
  Article PubMed Google Scholar
• Folini L, Veronelli A, Benetti A, et al. Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol. 2014;51(3):361–8. https://doi.org/10.1007/s00592-013-0516-4.
  Article CAS PubMed Google Scholar
• Jirapinyo P, McCarty TR, Dolan RD, Shah R, Thompson CC. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.03.017.
• Koc F, Kayaoglu HA, Celik A, et al. Effect of weight loss induced by intragastric balloon therapy on cardiac function in morbidly obese individuals: a pilot study. Med Princ Pract. 2015;24(5):432–5. https://doi.org/10.1159/000431177.
  Article PubMed PubMed Central Google Scholar
• Salomone F, Currenti W, Magrì G, Boškoski I, Zelber-Sagi S, Galvano F. Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis. Liver Int. 2021;41(9):2112–2116.
• van Baar AC, Beuers U, Wong K, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Rep. 2019;1(6):429–37.
  Article PubMed PubMed Central Google Scholar
• Steffen KJ, Engel SG, Pollert GA, Li C, Mitchell JE. Blood alcohol concentrations rise rapidly and dramatically after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2013;9(3):470–3.
  Article PubMed PubMed Central Google Scholar
• Volkow ND, Wang GJ, Tomasi D, Baler RD. The addictive dimensionality of obesity. Biol Psychiatry. 2013;73(9):811–8.
  Article PubMed PubMed Central Google Scholar
• Rieber N, Giel KE, Meile T, Enck P, Zipfel S, Teufel M. Psychological dimensions after laparoscopic sleeve gastrectomy: reduced mental burden, improved eating behavior, and ongoing need for cognitive eating control. Surg Obes Relat Dis. 2013;9(4):569–73. https://doi.org/10.1016/j.soard.2012.05.008.
  Article PubMed Google Scholar
• Gradus JL, Qin P, Lincoln AK, et al. Acute stress reaction and completed suicide. Int J Epidemiol. 2010;39(6):1478–84. https://doi.org/10.1093/ije/dyq112.
  Article PubMed Google Scholar
• Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56(12):3439–49. https://doi.org/10.1007/s10620-011-1767-y.
  Article CAS PubMed Google Scholar
• Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol Metab. 2017;6(2):62–72. https://doi.org/10.1097/xce.0000000000000126.
  Article Google Scholar
• Investigators THOPES. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):154–60. https://doi.org/10.1056/nejm200001203420302.
  Article Google Scholar
• Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol. 2008;28(2):341–7. https://doi.org/10.1161/ATVBAHA.107.153965.
  Article CAS PubMed Google Scholar
• Blum S, Vardi M, Brown JB, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010;11(5):675–84. https://doi.org/10.2217/pgs.10.17.
  Article CAS PubMed Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. https://doi.org/10.1056/NEJMoa0907929.
  Article CAS PubMed PubMed Central Google Scholar
• Bril F, Kalavalapalli S, Clark VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–566.e2. https://doi.org/10.1016/j.cgh.2017.12.001.
  Article CAS PubMed Google Scholar
• Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–307. https://doi.org/10.1056/NEJMoa060326.
  Article CAS PubMed Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE Randomized Controlled Trial. JAMA. 2008;299(13):1561–73. https://doi.org/10.1001/jama.299.13.1561.
  Article CAS PubMed Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–582.e1. https://doi.org/10.1053/j.gastro.2013.05.042.
  Article CAS PubMed Google Scholar
• Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3(1):5.
  PubMed PubMed Central Google Scholar
• Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17(4):16. https://doi.org/10.1007/s11883-015-0500-2.
  Article CAS Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–96. https://doi.org/10.1016/S0140-6736(19)33041-7.
  Article CAS PubMed Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65. https://doi.org/10.1016/S0140-6736(14)61933-4.
  Article CAS PubMed Google Scholar
• Pockros PJ, Fuchs M, Freilich B, et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39(11):2082–93.
  Article CAS PubMed Google Scholar
• Lucas K, Lopez P, Lawitz E, et al. Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR part C interim results. Dig Liver Dis. 2020;52:e38.
  Article Google Scholar
• Evaluating the safety, tolerability, and efficacy of GS-9674 in participants with nonalcoholic steatohepatitis. 2022. https://clinicaltrials.gov/ct2/show/NCT02854605. Accessed 1 Feb 2022.
• A Study to assess the safety, tolerability, pharmacokinetics and efficacy of EDP-305 in subjects with non-alcoholic steatohepatitis. 2022. https://clinicaltrials.gov/ct2/show/NCT03421431. Accessed 1 Feb 2022.
• Safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with NASH. 2022. https://clinicaltrials.gov/ct2/show/NCT02913105. Accessed 1 Feb 2022.
• Pedrosa M, Seyedkazemi S, Francque S, et al. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial. Contemp Clin Trials. 2020;88:105889. https://doi.org/10.1016/j.cct.2019.105889.
  Article PubMed Google Scholar
• Efficacy, safety and tolerability of the combination of tropifexor & licogliflozin and each monotherapy, compared with placebo in adult patients with NASH and liver fibrosis. (ELIVATE). https://clinicaltrials.gov/ct2/show/NCT04065841. Accessed 1 Feb 2022.
• Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1(10):1024–42. https://doi.org/10.1002/hep4.1108.
  Article CAS PubMed PubMed Central Google Scholar
• Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2021;160(1):219–31 e1.
  Article CAS PubMed Google Scholar
• Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis. 2022. https://www.natap.org/2020/AASLD/AASLD_129.htm. Accessed 1 Feb 2022.
• Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71(4):1198–212.
  Article CAS PubMed Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22. https://doi.org/10.1038/s41591-018-0104-9.
  Article CAS PubMed PubMed Central Google Scholar
• Yu X, Hao M, Liu Y, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol. 2019;864:172715.
  Article CAS PubMed Google Scholar
• Francque SM, Bedossa P, Ratziu V, et al. The PANPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: Results of the native phase 2b trial. Conference Abstract. Hepatology. 2020;72(1 SUPPL):9A–11A. https://doi.org/10.1002/hep.31578.
  Article Google Scholar
• Wong C, Lee MH, Yaow CYL, et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis. Systematic review. Front Endocrinol. 2021;12(332). https://doi.org/10.3389/fendo.2021.609110.
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. https://doi.org/10.1016/S0140-6736(15)00803-X.
  Article CAS PubMed Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020;384(12):1113–24. https://doi.org/10.1056/NEJMoa2028395.
  Article PubMed Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.
  Article CAS PubMed PubMed Central Google Scholar
• Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S90–S102. https://doi.org/10.2337/dc19-S009.
  Article Google Scholar
• Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547–58.
  Article CAS PubMed Google Scholar
• Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021;74(4):1809–1824.
• Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH). 2022. https://clinicaltrials.gov/ct2/show/NCT02704403. Accessed 1 Feb 2022.
• Loomba R, Mohseni R, Lucas KJ, et al. TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology. 2021;161(5):1475–86.
  Article CAS PubMed Google Scholar
• Loomba R, Kayali Z, Noureddin M, et al. GS-0976 Reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155(5):1463–1473.e6. https://doi.org/10.1053/j.gastro.2018.07.027.
  Article CAS PubMed Google Scholar
• Amin N, Carvajal-Gonzalez S, Aggarwal N, et al. PF-05221304 (PF'1304), A liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and alt-phase 2a, dose-ranging study. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2019:21A-22A.
• Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, phase 2a study (BALANCED). WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2020:6A-7A.
• Charles ED, Neuschwander-Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring). 2019;27(1):41–9. https://doi.org/10.1002/oby.22344.
  Article CAS Google Scholar
• Verzijl CRC, Van De Peppel IP, Struik D, Jonker JW. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. Expert Opin Investig Drugs. 2020;29(2):125–33. https://doi.org/10.1080/13543784.2020.1708898.
  Article CAS PubMed Google Scholar
• Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705–17. https://doi.org/10.1016/s0140-6736(18)31785-9.
  Article CAS PubMed Google Scholar
• Abdelmalek MF, Charles ED, Sanyal AJ, et al. The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials. 2021;104:106335. https://doi.org/10.1016/j.cct.2021.106335.
  Article PubMed Google Scholar
• Ratziu V, Ladron-De-Guevara L, Safadi R, et al. One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH. 2022. https://www.natap.org/2018/AASLD/AASLD_222.htm. Accessed 1 Feb 2022.
• Sinha RA, Bruinstroop E, Singh BK, Yen PM. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid. 2019;29(9):1173–91. https://doi.org/10.1089/thy.2018.0664.
  Article CAS PubMed Google Scholar
• Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14(5):259–69. https://doi.org/10.1038/nrendo.2018.10.
  Article CAS PubMed PubMed Central Google Scholar
• Sinha RA, You SH, Zhou J, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest. 2012;122(7):2428–38. https://doi.org/10.1172/jci60580.
  Article CAS PubMed PubMed Central Google Scholar
• Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14(5):259–69. https://doi.org/10.1038/nrendo.2018.10.
  Article CAS PubMed PubMed Central Google Scholar
• Sinha RA, You S-H, Zhou J, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest. 2012;122(7):2428–38. https://doi.org/10.1172/JCI60580.
  Article CAS PubMed PubMed Central Google Scholar
• Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012–24. https://doi.org/10.1016/S0140-6736(19)32517-6.
  Article CAS PubMed Google Scholar
• Harrison SA, Alkhouri N, Davison BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020;72(4):613–26. https://doi.org/10.1016/j.jhep.2019.10.023.
  Article CAS PubMed Google Scholar
• Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155(4):1140–53. https://doi.org/10.1053/j.gastro.2018.07.006.
  Article CAS PubMed Google Scholar
• Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334–1345.e5. https://doi.org/10.1053/j.gastro.2019.11.296.
  Article CAS PubMed Google Scholar
• Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26–39. https://doi.org/10.1016/j.jhep.2020.02.027.
  Article CAS PubMed Google Scholar
• Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72(5):816–27. https://doi.org/10.1016/j.jhep.2019.11.024.
  Article CAS PubMed Google Scholar
• Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69(10):1877–84. https://doi.org/10.1136/gutjnl-2019-319104.
  Article CAS PubMed Google Scholar
• Gilead announces topline results from phase 2 ATLAS study in patients with bridging fibrosis (F3) and compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). 2019. Accessed 6 January 2022, https://www.gilead.com/news-and-press/press-room/press-releases/2019/12/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-s
• Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73(2):625–43. https://doi.org/10.1002/hep.31622.
  Article CAS PubMed Google Scholar
• Bril F, Biernacki DM, Kalavalapalli S, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–8. https://doi.org/10.2337/dc19-0167.
  Article CAS PubMed Google Scholar
• Pockros PJ, Fuchs M, Freilich B, et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39(11):2082–93. https://doi.org/10.1111/liv.14209.
  Article CAS PubMed Google Scholar
• Chen SC, Tsai SP, Jhao JY, Jiang WK, Tsao CK, Chang LY. Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 diabetes: a prospective study of 132,377 adults. Sci Rep. 2017;7(1):4649. https://doi.org/10.1038/s41598-017-04631-7.
  Article CAS PubMed PubMed Central Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. https://doi.org/10.1002/hep.25762.
  Article PubMed Google Scholar
• Farah S, Nguyen T, Kelsberg G, Safranek S. Metformin for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Am Fam Physician. 2019;99(4):262–3.
  PubMed Google Scholar
• 9 Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–s102. https://doi.org/10.2337/dc19-S009
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. https://doi.org/10.1016/s0140-6736(15)00803-x.
  Article CAS PubMed Google Scholar
• Bril F, Kalavalapalli S, Clark VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–566.e2. https://doi.org/10.1016/j.cgh.2017.12.001.
  Article CAS PubMed Google Scholar
• Aneni EC, Oni ET, Martin SS, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–14. https://doi.org/10.1097/hjh.0000000000000532.
  Article CAS PubMed Google Scholar
• Muthiah MD, Sanyal AJ. Current management of non-alcoholic steatohepatitis. Liver Int. 2020;40 Suppl 1(Suppl 1):89–95. https://doi.org/10.1111/liv.14355.
  Article PubMed Google Scholar
• Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40(5):1222–5. https://doi.org/10.1002/hep.20420.
  Article CAS PubMed Google Scholar
• Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;15(8):942–54. https://doi.org/10.3748/wjg.15.942.
  Article CAS PubMed PubMed Central Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79–104. https://doi.org/10.1002/hep.23623.
  Article CAS PubMed Google Scholar
• Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13(5):297–310. https://doi.org/10.1038/nrneph.2017.16.
  Article CAS PubMed Google Scholar
• Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12(2):322–6. https://doi.org/10.3748/wjg.v12.i2.322.
  Article CAS PubMed PubMed Central Google Scholar
• Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926–31. https://doi.org/10.1111/jgh.12643.
  Article PubMed Google Scholar
• Atan NAD, Koushki M, Motedayen M, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10(Suppl1):S1.
  Google Scholar
• Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the hepatologist should know? Ann Hepatol. 2020;19(2):134–44. https://doi.org/10.1016/j.aohep.2019.07.013.
  Article PubMed Google Scholar
• Dyson JK, Anstee QM, McPherson S. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J. 2015;91(1072):92–101. https://doi.org/10.1136/postgradmedj-2013-100404rep.
  Article CAS PubMed Google Scholar
• Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21(25):7860–8. https://doi.org/10.3748/wjg.v21.i25.7860.
  Article CAS PubMed PubMed Central Google Scholar
• Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43(10):990–4. https://doi.org/10.1097/MCG.0b013e31819c392e.
  Article CAS PubMed Google Scholar
• Henson JB, Patel YA, Muir AJ. Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54(11-12):1481–9. https://doi.org/10.1111/apt.16646.
  Article PubMed Google Scholar
• Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61(6):1714–20. https://doi.org/10.1007/s10620-015-4000-6.
  Article CAS PubMed Google Scholar
• Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287–92. https://doi.org/10.1053/j.gastro.2004.02.015.
  Article CAS PubMed Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000000625.
  Article PubMed Google Scholar
• Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005;11(31):4838–42. https://doi.org/10.3748/wjg.v11.i31.4838.
  Article PubMed PubMed Central Google Scholar
• Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13. https://doi.org/10.1016/s2468-1253(21)00308-3.
  Article PubMed Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50. https://doi.org/10.1056/NEJMra0912063.
  Article CAS PubMed Google Scholar
• Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8. https://doi.org/10.1016/j.cgh.2008.11.005.
  Article PubMed Google Scholar
• Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. https://doi.org/10.1002/hep.23314.
  Article PubMed Google Scholar
• Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600. https://doi.org/10.1016/j.jhep.2016.05.013.
  Article PubMed Google Scholar
• Toh JZK, Pan XH, Tay PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.09.021.
• Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25(5):1045–50. https://doi.org/10.1161/01.Atv.0000160613.57985.18.
  Article CAS PubMed Google Scholar
• Mantovani A, Dauriz M, Sandri D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 2019;39(4):758–69. https://doi.org/10.1111/liv.14044.
  Article PubMed Google Scholar
• Markus MRP, Baumeister SE, Stritzke J, et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population. Arterioscler Thromb Vasc Biol. 2013;33(7):1690–5. https://doi.org/10.1161/ATVBAHA.112.300556.
  Article CAS PubMed Google Scholar
• Markus MR, Meffert PJ, Baumeister SE, et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the study of health in Pomerania (SHIP). Atherosclerosis. 2016;245:123–31. https://doi.org/10.1016/j.atherosclerosis.2015.12.023.
  Article CAS PubMed Google Scholar
• Mantovani A, Rigamonti A, Bonapace S, et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care. 2016;39(8):1416–23.
  Article CAS PubMed Google Scholar
• Valbusa F, Agnoletti D, Scala L, et al. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162–8. https://doi.org/10.1016/j.ijcard.2018.04.129.
  Article PubMed Google Scholar
• Valbusa F, Bonapace S, Grillo C, et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine (Baltimore). 2016;95(7):e2760–0. https://doi.org/10.1097/MD.0000000000002760.
  Article CAS Google Scholar
• Valbusa F, Bonapace S, Agnoletti D, et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One. 2017;12(3):e0173398–8. https://doi.org/10.1371/journal.pone.0173398.
  Article CAS PubMed PubMed Central Google Scholar
• Bonapace S, Valbusa F, Bertolini L, et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One. 2014;9(2):e88371. https://doi.org/10.1371/journal.pone.0088371.
  Article CAS PubMed PubMed Central Google Scholar
• Mantovani A, Pernigo M, Bergamini C, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. 2015;64(8):879–87. https://doi.org/10.1016/j.metabol.2015.04.003.
  Article CAS PubMed Google Scholar
• Jiang ZG, Feldbrügge L, Tapper EB, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016;43(6):734–43. https://doi.org/10.1111/apt.13515.
  Article CAS PubMed Google Scholar
• Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(13):2776–2784.e4. https://doi.org/10.1016/j.cgh.2019.04.061.
  Article CAS PubMed PubMed Central Google Scholar
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. https://doi.org/10.1016/s0140-6736(09)60503-1.
  Article PubMed Google Scholar
• Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277–87. https://doi.org/10.1001/jama.2018.20578.
  Article CAS PubMed PubMed Central Google Scholar
• Alkhouri N, Tincopa M, Loomba R, Harrison SA. What does the future hold for patients with nonalcoholic steatohepatitis: diagnostic strategies and treatment options in 2021 and beyond? Hepatol Commun. 2021;5(11):1810–23. https://doi.org/10.1002/hep4.1814.
  Article PubMed PubMed Central Google Scholar